
CLAIMS

1. A crystalline solid form of Compound 1:



Compound 1

wherein the crystalline solid form is a hydrate and is characterized by one or more peaks in its X-ray powder diffraction pattern selected from 5.9, 8.1, 9.5, 16.2, 16.6, 17.8, 18.9, and 32.6 ± 0.2 degrees 2-theta.

2. The crystalline solid form of claim 1, wherein the crystalline solid form is characterized by one or more peaks in its X-ray powder diffraction pattern selected from:

°2θ (± 0.2)
5.9
8.1
9.5
10.6
13.5
15.1
15.8
16.2
16.6
16.9
17.8
18.9
20.7
21.1
21.5
23.2
23.7
24.4
24.9
25.5
27.5

°2θ (± 0.2)
28.6
30.3
32.6
33.5
34.7
36.2
40.8
41.6.

3. The crystalline solid form of claim 1 or claim 2, wherein the crystalline solid form is characterized by an X-ray powder diffraction pattern substantially similar to FIG. 1A.

4. The crystalline solid form of any one of claims 1-3, wherein the crystalline solid form is Form 1.

5. A sample comprising the crystalline form of any one of claims 1-4, wherein the sample is substantially free of impurities.

6. A pharmaceutical formulation comprising the crystalline form of any one of claims 1-4, and one or more pharmaceutically acceptable excipients.

7. The pharmaceutical formulation of claim 6, wherein the pharmaceutical formulation comprises:

about 10-30% by weight of the crystalline solid form of Compound 1, calculated by free base weight;

about 1-10% by weight of a disintegrant;

about 1-10% by weight of a binder; and

about 0.05-0.5% by weight of an antioxidant.

8. The pharmaceutical formulation of claim 7, further comprising a lubricant.

9. The pharmaceutical formulation of claims 7 or 8, wherein the binder is hydroxypropyl cellulose.

10. The pharmaceutical formulation of any one of claims 7-9, wherein the disintegrant is croscarmellose sodium.

11. The pharmaceutical formulation of any one of claims 7-10, wherein the antioxidant is vitamin E.

12. The pharmaceutical formulation of any one of claims 7-11, wherein the pharmaceutical formulation comprises about 20 mg to about 120 mg of the crystalline solid form of Compound 1, calculated by free base weight.

13. The pharmaceutical formulation of claim 12, wherein the pharmaceutical formulation comprises about 40 mg to about 80 mg of the crystalline solid form of Compound 1, calculated by free base weight.

14. The pharmaceutical formulation of any one of claims 6-13, wherein the pharmaceutical formulation is a unit dosage form.

15. The pharmaceutical formulation of claim 14, wherein the unit dosage form is in the form of a tablet.

16. Use of the crystalline form of any one of claims 1-4, or the pharmaceutical formulation of any one of claims 6-15 in the manufacture of a medicament for treating a disease, disorder, or condition, in a subject in need thereof.

17. The use of claim 16, wherein the disease, disorder, or condition is selected from atopic dermatitis, alopecia areata, hand and foot eczema, chronic hand eczema, hidradenitis suppurativa, pemphigus vulgaris, psoriasis, cutaneous lupus, vitiligo, inflammatory bowel disease, rheumatoid arthritis, asthma, allergic rhinitis, systemic lupus erythematosus, psoriatic arthritis, multiple sclerosis, acute myeloid leukemia, graft versus host disease, myelofibrosis, warm hemolytic

anemia, idiopathic thrombocytopenic purpura, immunoglobulin A nephropathy, scleroderma, idiopathic pulmonary fibrosis, uveitis, eosinophilic esophagitis, and lupus nephritis.